# IXICO and Medidata collaborate to create an advanced neuroimaging clinical trials platform 26 Mar 26 news # IXICO and Medidata collaborate to create an advanced neuroimaging clinical trials platform [ ](https://x.com/intent/tweet?url=https://ixico.com/news-and-resources/news/ixico-and-medidata-collaborate-to-create-an-advanced-neuroimaging-clinical-trials-platform/) [ ](https://bsky.app/intent/compose?text=https://ixico.com/news-and-resources/news/ixico-and-medidata-collaborate-to-create-an-advanced-neuroimaging-clinical-trials-platform/) [ ](https://www.facebook.com/sharer/sharer.php?u=https://ixico.com/news-and-resources/news/ixico-and-medidata-collaborate-to-create-an-advanced-neuroimaging-clinical-trials-platform/) [ ](https://www.linkedin.com/shareArticle?mini=true&url=https://ixico.com/news-and-resources/news/ixico-and-medidata-collaborate-to-create-an-advanced-neuroimaging-clinical-trials-platform/) ![MEDIDATA Press Release 3](/assets/blog-images/MEDIDATA-Press-Release_3__ScaleMaxWidthWzgwMF0_FillMaxWzgwMCw0NTBd_ExtRewriteWyJqcGciLCJ3ZWJwIl0.webp)**26 March 2026, IXICO plc (AIM: IXI) – London, UK.** IXICO, a global leader in neuroscience imaging and biomarker analytics, using its AI-driven platform to help advance drug development in neurological disorders, today announced it is aligning its IXI™ Platform with Medidata, a Dassault Systèmes brand and leading provider of clinical trial solutions to the life sciences industry, to support clinical research. The technology collaboration will create a unique neuroimaging data and analysis offering linking IXICO’s IXI™ Platform with the Medidata Platform to deliver a differentiated, unified user experience for customers. This powerful combination will enable biopharma companies to conduct neuroimaging clinical trials with streamlined reporting of eligibility and safety criteria and to collect, upload, manage, and receive analysis on complex neuroimaging data within a highly secure, regulatory-compliant system. The collaboration is expected to provide IXICO with expanded scale, opportunities for technological co-development, market reach, and an additional route to market beyond its existing commercial activities. The agreement is non-exclusive and IXICO will continue to contract directly with biopharma clients and seek other partnership opportunities outside of joint commercial activities with Medidata. **Bram Goorden, Chief Executive Officer of IXICO, commented:** “This is an exciting opportunity to power the future of neuroimaging clinical trials. This commercial agreement supports our strategy to expand the reach of our platform and analytics capabilities and serve some of the most important clinical programs and biopharma customers at scale. Medidata is a highly respected global leader in life science solutions, and we are delighted to be working with them.” **Wayne Walker, Senior Vice President, Data Experience at Medidata, commented:** “Through this collaboration, both IXICO and Medidata can expand their impact in Central Nervous System clinical trials. Medidata’s ability to deliver precise data for complex neurological conditions will elevate IXICO’s proprietary platform, empowering CROs to deliver a vastly superior, unified experience to their biopharma sponsors and accelerating the critical clinical research needed to treat neurological disorders.” [ Back to News ](/news-and-resources/news/) ### Recents ![IXICO announces £2.7 million Phase 3 contract win in Huntington’s disease](/assets/blog-images/HD-contract-win__ScaleMaxWidthWzgwMF0_FillMaxWzgwMCw0NTBd_ExtRewriteWyJwbmciLCJ3ZWJwIl0.webp) 2 Nov 26 news [IXICO announces £2.7 million Phase 3 contract win in Huntington’s disease](/news-and-resources/news/2-7-million-phase-3-contract-win-in-huntingtons-disease/) [IXICO presents research on novel methods to reduce unwanted variability in Huntington’s disease biomarker data ](/news-and-resources/news/ixico-presents-research-on-novel-methods-to-reduce-unwanted-variability-in-huntingtons-disease-biomarker-data/) [IXICO announces two contracts in Alzheimer's disease worth £1.5 million](/news-and-resources/news/ixico-announces-two-contracts-in-alzheimers-disease-worth-1-5-million/) [IXICO announces 28% expected revenue growth for FY26](/news-and-resources/news/ixico-trading-update-for-year-ending-30-september-2026/) [IXICO to present advancements in neuroimaging for Parkinson’s disease at European radiology conference ](/news-and-resources/news/ixico-to-present-advancements-in-neuroimaging-for-parkinsons-disease/) ### Library [November 2026](/news-and-resources/news/archive/2026/11/) [October 2026](/news-and-resources/news/archive/2026/10/) [September 2026](/news-and-resources/news/archive/2026/09/) [July 2026](/news-and-resources/news/archive/2026/07/) [June 2026](/news-and-resources/news/archive/2026/06/) [May 2026](/news-and-resources/news/archive/2026/05/) [April 2026](/news-and-resources/news/archive/2026/04/) [March 2026](/news-and-resources/news/archive/2026/03/) [February 2026](/news-and-resources/news/archive/2026/02/) [January 2026](/news-and-resources/news/archive/2026/01/) [2025](/news-and-resources/news/archive/2025/) [2024](/news-and-resources/news/archive/2024/) [2023](/news-and-resources/news/archive/2023/) [2022](/news-and-resources/news/archive/2022/) [2021](/news-and-resources/news/archive/2021/) [2020](/news-and-resources/news/archive/2020/) [2019](/news-and-resources/news/archive/2019/)